Intratumoral Canine Distemper Virus Infection Inhibits Tumor Growth by Modulation of the Tumor Microenvironment in a Murine Xenograft Model of Canine Histiocytic Sarcoma
Authors:
- Federico ArmandoFederico Armando
- Adnan FayyadAFAdnan Fayyad
- Stefanie ArmsSAStefanie Arms
- Yvonne BarthelYBYvonne Barthel
- Dirk SchaudienDSDirk Schaudien
- Karl RohnKRKarl Rohn
- Matteo GambiniMGMatteo Gambini
- Mara Sophie LombardoMLMara Sophie Lombardo
- Andreas BeinekeABAndreas Beineke
- Wolfgang BaumgärtnerWBWolfgang Baumgärtner
- Christina PuffCPChristina Puff
Open Access
- 30 March 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (7) , 3578
Abstract
Histiocytic sarcomas refer to highly aggressive tumors with a poor prognosis that respond poorly to conventional treatment approaches. Oncolytic viruses, which have gained significant traction as a cancer therapy in recent decades, represent a promising option for treating histiocytic sarcomas through their replication and/or by modulating the tumor microenvironment. The live attenuated canine distemper virus (CDV) vaccine strain Onderstepoort represents an attractive candidate for oncolytic viral therapy. In the present study, oncolytic virotherapy with CDV was used to investigate the impact of this virus infection on tumor cell growth through direct oncolytic effects or by virus-mediated modulation of the tumor microenvironment with special emphasis on angiogenesis, expression of selected MMPs and TIMP-1 and tumor-associated macrophages in a murine xenograft model of canine histiocytic sarcoma. Treatment of mice with xenotransplanted canine histiocytic sarcomas using CDV induced overt retardation in tumor progression accompanied by necrosis of neoplastic cells, increased numbers of intratumoral macrophages, reduced angiogenesis and modulation of the expression of MMPs and TIMP-1. The present data suggest that CDV inhibits tumor growth in a multifactorial way, including direct cell lysis and reduction of angiogenesis and modulation of MMPs and their inhibitor TIMP-1, providing further support for the concept of its role in oncolytic therapies.Keywords
This publication has 68 references indexed in Scilit:
- Mounting a strategic offense: fighting tumor vasculature with oncolytic virusesTrends in Molecular Medicine, 2013
- Natural Oncolytic Activity of Live-Attenuated Measles Virus against Human Lung and Colorectal AdenocarcinomasBioMed Research International, 2013
- Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumorsBMC Cancer, 2012
- Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue SarcomaPLOS ONE, 2012
- Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patientsJournal of Translational Medicine, 2012
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Evaluation of Artificial Dermis Neovascularization in an Avascular WoundJournal of Reconstructive Microsurgery, 2009
- Pathogenesis and immunopathology of systemic and nervous canine distemperVeterinary Immunology and Immunopathology, 2009
- Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood FlowMolecular Therapy, 2007
- In vitroCanine Distemper Virus Infection of Canine Lymphoid Cells: A Prelude to Oncolytic Therapy for LymphomaClinical Cancer Research, 2005